IP Library Granted Patent US 7,452,543
Granted Patent B2
US 7,452,543 · App. 11/257,500 · Granted Nov 18, 2008

Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,452,543
App. No.
11/257,500
Granted
Nov 18, 2008
Kind
B2
Abstract

A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.

Claims (8)

1. An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising: a galactose-binding lectin; an L-chain of a clostridial neurotoxin or a fragment thereof that cleaves vesicle and/or plasma membrane associated proteins involved in the exocytic process; and a translocating domain of a clostridial neurotoxin H-chain that translocates the L-chain or L-chain fragment into a target cell, wherein the agent is a fusion protein.

2. An agent according to claim 1 , wherein the galactose-binding lectin is selected from the group consisting of Erythrina cristagalli lectin, Erythrina corallodendron lectin, soybean agglutinin, Arachis hypogaea lectin, Bandeirea simplicfolia lectin and Pseudomonas aeringuosa lectin.

3. An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising: a galactose-binding lectin; an L-chain of a clostridial neurotoxin or a fragment thereof that cleaves vesicle and/or plasma membrane associated proteins involved in the exocytic process; and a translocating domain of a diphtheria toxin that translocates the L-chain or L-chain fragment into a target cell, wherein the agent is a fusion protein.

4. An agent according to claim 3 , wherein the galactose-binding lectin is selected from the group consisting of Erythrina cristagalli lectin, Erythrina corallodendron lectin, soybean agglutinin, Arachis hypogaea lectin, Bandeirea simplicifolia lectin and Pseudomonas aeringuosa lectin.

5. An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising: a galactose-binding lectin; an IgA protease of Neisseria gonorrhoeae that cleaves vesicle and/or plasma membrane associated proteins involved in the exocytic process; and a translocating domain of a clostridial neurotoxin H-chain that translocates the IgA protease into a target cell, wherein the agent is a fusion protein.

6. An agent according to claim 5 , wherein the galactose-binding lectin is selected from the group consisting of Erythrina cristagalli lectin, Erythrina corallodendron lectin, soybean agglutinin, Arachis hypogaea lectin, Bandeirea simplicifolia lectin and Pseudomonas aeringuosa lectin.

7. An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising: a galactose-binding lectin; an IgA protease of Neisseria gonorrhoeae that cleaves vesicle and/or plasma membrane associated proteins involved in the exocytic process; and a translocating domain of a diphtheria toxin that translocates the IgA protease into a target cell, wherein the agent is a fusion protein.

8. An agent according to claim 7 , wherein the galactose-binding lectin is selected from the group consisting of Erythrina cristagalli lectin, Erythrina corallodendron lectin, soybean agglutinin, Arachis hypogaea lectin, Bandeirea simplicifolia lectin and Pseudomonas aeringuosa lectin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2008
From: IPSEN LIMITED; HEALTH PROTECTION AGENCY
To: SYNTAXIN LIMITED
Reel/Frame 021076/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2006
From: CHADDOCK, JOHN ANDREW; MARKS, PHILIP; DUGGAN, MICHAEL JOHN
To: HEALTH PROTECTION AGENCY; IPSEN LIMITED
Reel/Frame 017751/0814 →